FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Rolex Rings IPO and Tatva Chintan Pharma IPO.
Rolex Rings IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Tatva Chintan Pharma IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.
Rolex Rings IPO | Tatva Chintan Pharma IPO | |
---|---|---|
Logo | ||
Issue Category | Mainline | Mainline |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | BSE, NSE | BSE, NSE |
Lead Managers | Equirus Capital Private Limited Idbi Capital Market Services Limited Jm Financial Limited |
ICICI Securities Limited Jm Financial Limited |
Registrar | Link Intime India Private Ltd | Link Intime India Private Ltd |
Market Maker | ||
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | ||
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Rolex Rings IPO is up to ₹731.00 Cr whereas the issue size of the Tatva Chintan Pharma IPO is up to ₹500.00 Cr. The final issue price of Rolex Rings IPO is ₹900.00 per share and of Tatva Chintan Pharma IPO is ₹1,083.00 per share.
Rolex Rings IPO | Tatva Chintan Pharma IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹880.00 per share | ₹1,073.00 per share |
Issue Price (Upper) | ₹900.00 per share | ₹1,083.00 per share |
Issue Price (Final) | ₹900.00 per share | ₹1,083.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 16 shares | 13 shares |
Fresh Issue Size | ||
Fresh Issue Size (Amount) | up to ₹56.00 Cr | up to ₹225.00 Cr |
OFS Issue Size | 75,00,000 shares | |
OFS Issue Size (Amount) | up to ₹675.00 Cr | up to ₹275.00 Cr |
Issue Size Total | ||
Issue Size Total (Amount) | up to ₹731.00 Cr | up to ₹500.00 Cr |
Rolex Rings IPO opens on Jul 28, 2021, while Tatva Chintan Pharma IPO opens on Jul 16, 2021. The closing date of Rolex Rings IPO and Tatva Chintan Pharma IPO is Jul 30, 2021, and Jul 20, 2021, respectively.
Rolex Rings IPO | Tatva Chintan Pharma IPO | |
---|---|---|
Anchor Bid Date | ||
Issue Open | Jul 28, 2021 | Jul 16, 2021 |
Issue Close | Jul 30, 2021 | Jul 20, 2021 |
Basis Of Allotment (Tentative) | Aug 04, 2021 | Jul 26, 2021 |
Initiation of Refunds (Tentative) | Aug 05, 2021 | Jul 27, 2021 |
Credit of Share (Tentative) | Aug 06, 2021 | Jul 28, 2021 |
Listing date (Tentative) | Aug 09, 2021 | Jul 29, 2021 |
Anchor Lockin End date 1 | Sep 03, 2021 | Aug 25, 2021 |
Anchor Lockin End date 2 | Nov 02, 2021 | Oct 24, 2021 |
Rolex Rings IPO P/E ratio is , as compared to Tatva Chintan Pharma IPO P/E ratio of .
Rolex Rings IPO | Tatva Chintan Pharma IPO | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial |
|
|
||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 58.99% | 100% | ||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 57.64% | 79.17% | ||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||
ROE | ||||||||||||||||||||||||||||||||||||||||||||||
ROCE | ||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | ||||||||||||||||||||||||||||||||||||||||||||||
EPS | ||||||||||||||||||||||||||||||||||||||||||||||
RoNW |
In the Rolex Rings IPO retail investors (RII) are offered 28,42,778 shares while in Tatva Chintan Pharma IPO retail investors are offered 28,42,778 shares. Qualified institutional buyers (QIB) are offered 16,24,444 shares in Rolex Rings IPO and 9,31,966 shares in Tatva Chintan Pharma IPO.
Rolex Rings IPO | Tatva Chintan Pharma IPO | |
---|---|---|
Anchor Investor Reserveration | ||
Market Maker Reserveration | ||
QIB | 16,24,444 shares | 9,31,966 shares |
NII | 12,18,334 shares | 6,98,975 shares |
RII | 28,42,778 shares | 16,30,941 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 56,85,556 shares | 32,61,882 shares |
Rolex Rings IPO subscribed 130.44x in total, whereas Tatva Chintan Pharma IPO subscribed 180.36x.
Rolex Rings IPO | Tatva Chintan Pharma IPO | |
---|---|---|
QIB (times) | 143.58x | 185.23x |
NII (times) | 360.11x | 512.22x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 24.49x | 35.35x |
Employee (times) | ||
Other (times) | ||
Total (times) | 130.44x | 180.36x |
Add a public comment...
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|